Anthropometric and reproductive factors and risk of esophageal and gastric cancer by subtype and subsite: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort

Harinashi Sanikini, David C. Muller, Marisa Sophiae, Sabina Rinaldi, Antonio Agudo, Eric J. Duell, Elisabete Weiderpass, Kim Overvad, Anne Tjonneland, Jytte Halkjær, Marie-Christine Boutron-Ruault, Franck Carbonnel, Iris Cervenka, Heiner Boeing, Rudolf Kaaks, Tilman Kühn, Antonio Trichopoulou, Georgia Martimianaki, Anna Karakatsans, Valeria Pala, Domenico Palli, Amalia Mattiello, Rosario Tumino, Carlotta Sacerdote, Guri Skeie, Charlotte Rylander, Maria-Dolores Chirlaque López, Maria-Jose Sánchez, Eva Ardanaz, Sara Regnér, Tanja Stocks, Bas Bueno-de-Mesquita, Roel C.H. Vermeulen, Dagfinn Aune, Tammy Y.N. Tong, Nathalie Kliemann, Neil Murphy, Marc Chadeau-Hyam, Marc J. Gunter and Amanda J. Cross

1Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
2Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France
3Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
4Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway
5Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway
6Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
7Genetic Epidemiology Group, Folkhälsan Research Center, Faculty of Medicine, University of Helsinki, Helsinki, Finland
8Department of Public Health, Aarhus University, Aarhus, Denmark
9Danish Cancer Society Research Center, Copenhagen, Denmark
10CESP, Faculté de Médecine, Université Paris-Sud, Villejuif, France

Key words: obesity, reproductive, hormones, esophageal, gastric, cancer
Abbreviations: BMI: body mass index; CI: confidence intervals; EA: esophageal adenocarcinoma; EPIC: European Prospective Investigation into Cancer and Nutrition; ESCC: esophageal squamous cell carcinoma; GC: gastric cardia; GNC: gastric noncardia; HC: hip circumference; HR: hazard ratio; WC: waist circumference; WHR: waist-to-hip ratio; WHtR: waist-to-height ratio

Additional Supporting Information may be found in the online version of this article.
Conflict of interest: None of the authors have any conflicts of interest to disclose.
Grant sponsor: Medical Research Council; Grant numbers: MR/M012190/1, 1000143; Grant sponsor: Cancer Research UK;
Grant numbers: C8221/A19170, C570/A16491, 14136; Grant sponsor: County Councils of Skåne and Västerbotten (Sweden); Grant sponsor: Swedish Research Council; Grant sponsor: Swedish Cancer Society; Grant sponsor: Catalan Institute of Oncology (Spain); Grant sponsor: Regional Governments of Andalucia, Asturias, Basque Country, Murcia; Grant number: 6236; Grant sponsor: Health Research Fund (FIS); Grant numbers: C33889/A20189, PI13/01162, PI13/00061; Grant sponsor: National Institute for Public Health and the Environment (Bilthoven, The Netherlands); Grant sponsor: Statistics Netherlands; Grant sponsor: World Cancer Research Fund (WCRF); Grant sponsor: Dutch ZON (Zorg Onderzoek Nederland); Grant sponsor: Dutch Prevention Funds; Grant sponsor: LK Research Funds; Grant sponsor: Netherlands Cancer Registry (NKR); Grant sponsor: Dutch Ministry of Public Health, Welfare and Sports (VWS); Grant sponsor: National Research Council (Italy); Grant sponsor: Associazione Italiana per la Ricerca sul Cancro- AIRC-Italy; Grant sponsor: Hellenic Health Foundation (Greece); Grant sponsor: Federal Ministry of Education and Research (Germany); Grant sponsor: Deutsches Krebsforschungszentrum; Grant sponsor: Deutsche Krebshilfe; Grant sponsor: Federal Ministry of Education and Research (BMBF); Grant sponsor: German Cancer Research Centre (DKFZ); Grant sponsor: German Cancer Aid; Grant sponsor: Institut National de la Santé et de la Recherche Médicale (INSERM, France); Grant sponsor: Mutuelle Générale de l’Éducation Nationale; Grant sponsor: Institut Gustave Roussy; Grant sponsor: Ligue Contre le Cancer; Grant sponsor: Danish Cancer Society (Denmark); Grant sponsor: International Agency for Research on Cancer; Grant sponsor: European Commission (DG-SANCO); Grant sponsor: Stand Up to Cancer campaign for Cancer Research UK
DOI: 10.1002/ijc.32386

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

History: Received 27 Nov 2018; Accepted 28 Mar 2019; Online 3 May 2019
Correspondence to: Dr Harinashi Sanikini, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, St. Mary’s Campus, Norfolk Place, London W2 1PG, United Kingdom, Tel.: +44-20-7594-9652, E-mail: h.sanikini@imperial.ac.uk
Anthropometric and hormonal factors and upper gastrointestinal cancer

Obesity has been associated with upper gastrointestinal cancers; however, there are limited prospective data on associations by subtype/subsite. Obesity can impact hormonal factors, which have been hypothesized to play a role in these cancers. We investigated anthropometric and reproductive factors in relation to esophageal and gastric cancer by subtype and subsite for 476,160 participants from the European Prospective Investigation into Cancer and Nutrition cohort. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox models. During a mean follow-up of 14 years, 220 esophageal adenocarcinomas (EA), 195 esophageal squamous cell carcinomas, 243 gastric cardiac (GC) and 373 gastric non-cardia (GNC) cancers were diagnosed. Body mass index (BMI) was associated with EA in men (BMI ≥ 30 vs. 18.5–25 kg/m²: HR = 1.94, 95% CI: 1.25–3.03) and women (HR = 2.66, 95% CI: 1.15–6.19); however, adjustment for waist-to-hip ratio (WHR) attenuated these associations. After mutual adjustment for BMI and HC, respectively, WHR and waist circumference (WC) were associated with EA in men (HR = 3.47, 95% CI: 1.99–6.06 for WHR ≥ 0.96 vs. <0.91; HR = 2.67, 95% CI: 1.52–4.72 for WC >98 vs. <90 cm) and women (HR = 4.40, 95% CI: 1.35–14.33 for WHR ≥ 0.82 vs. <0.76; HR = 5.67, 95% CI: 1.76–18.26 for WC >84 vs. <74 cm). WHR was also positively associated with GC in women, and WC was positively associated with GC in men. Inverse associations were observed between parity and EA (HR = 0.38, 95% CI: 0.14–0.99; >2 vs. 0) and age at first pregnancy and GNC (HR = 0.54, 95% CI: 0.32–0.91; >26 vs. ≤22 years); whereas bilateral ovariectomy was positively associated with GNC (HR = 1.87, 95% CI: 1.04–3.36). These findings support a role for hormonal pathways in upper gastrointestinal cancers.

What’s new?
Obesity can change the body’s hormone balance, and encourage the onset of cancer. Here, the authors investigated the relationship between obesity, hormones, and esophageal and gastric cancers. Using data from the EPIC cohort, they obtained information about anthropometric and reproductive factors for 476,160 participants. Excess fat around the waist, they found, was associated with esophageal adenocarcinoma and gastric cardiac cancer, in women and men. In women, bearing children, as well as younger age at first pregnancy, had an inverse association with certain cancers. Ovariectomy was positively associated with gastric non-cardia cancer, suggesting involvement of hormone pathways in these malignancies.
**Introduction**

Esophageal cancer is the seventh most common and gastric cancer the fifth most common cancer worldwide, with an estimated 572,000 and 1,000,000 cases in 2018, respectively. These cancers are more common in men than in women and are becoming more prevalent in many regions of the world. Esophageal cancer can be categorized histologically as esophageal adenocarcinoma (EA) and esophageal squamous cell carcinoma (ESCC) and these subtypes have distinct etiologies. Gastric cancers are predominantly adenocarcinomas but their etiology appears to differ depending on their location in the gastric cardia (GC) or gastric noncardia (GNC). Smoking and alcohol are well-known risk factors for ESCC, whereas gastroesophageal reflux disease (GERD), smoking and obesity are established risk factors for EA. Smoking and obesity are also thought to be risk factors for GC, while *Helicobacter pylori* infection and smoking are risk factors for GNC.

The role of obesity in upper gastrointestinal cancers has been previously investigated in a number of epidemiological studies. Two studies conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, reported a positive association between body mass index (BMI) and EA. Two other analyses found a positive association between BMI and risk of EA and GC. In addition, the recent report from the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) concluded that there is “convincing” evidence that BMI increases the risk of EA. Conversely, an inverse association between BMI and ESCC risk has been reported in several epidemiological studies. The WCRF/AICR report also concluded that there is “probable” evidence that BMI increases the risk of GC. However, few epidemiological studies have examined the association between abdominal obesity and risk of esophageal and gastric cancer by subtype or subsite and the published findings are inconsistent.

There are several plausible biological mechanisms underlying the association between obesity and upper gastrointestinal cancers. Obesity promotes GERD and its transition to Barrett’s esophagus, which increases the risk of EA and GC. Obesity is also associated with a range of metabolic and endocrinologic abnormalities. In particular, obesity can lead to insulin resistance, where circulating levels of insulin and bioavailable insulin-like growth factor (IGF) are elevated, leading to stimulation of cell proliferation and downregulation of apoptosis. Obese individuals also have abnormal circulating levels of adipokines (e.g., higher levels of leptin and lower levels of adiponectin), proinflammatory cytokines (e.g., tumor necrosis factor-α and interleukin-6) and endogenous sex steroids, which are synthesized in peripheral adipose tissue and may contribute to cancer development.

In addition to the link through obesity, sex hormones could also explain the predominance of both esophageal and gastric cancers in men compared to women. It has been suggested that female sex hormones, particularly estrogens, may protect against the development of esophageal and gastric cancer. Some epidemiological studies have investigated the role of hormonal and reproductive factors in the development of esophageal and gastric cancer risk; however, prospective studies examining these relationships by subtype of esophageal cancer and subsite of gastric cancer are limited, with conflicting results. The association between reproductive factors and gastric cancer was investigated in a previous analysis of the EPIC cohort, which included participants with follow-up through 2004; this analysis showed a positive association between ovariectomy and gastric cancer risk. In the present study, not only did we have much longer follow-up of the EPIC cohort data, and therefore more cases, but also we studied the role of reproductive factors in both esophageal and gastric cancer by subtype and subsite.

The aim of the current study was to investigate both anthropometric and reproductive factors in relation to esophageal and gastric cancer by subtype and subsite, respectively, in a large cohort study with long-term follow-up.

**Materials and Methods**

**Study population**

The EPIC study is an ongoing multicenter prospective cohort study aimed at investigating the association between diet, lifestyle, genetic and environmental factors and the development of cancer and other chronic diseases. The methodological details and rationale of the EPIC study have been described previously. In brief, the cohort comprises of 521,448 men and women, aged 25–70 years, recruited between 1992 and 2000 from 23 centers located in 10 European countries including Denmark, France, Germany, Greece, Italy, Norway, Spain, Sweden, the Netherlands and the United Kingdom. Participants were mostly recruited from the general population with some exceptions: French participants were recruited via health insurance databases; some participants of the Italian and Spanish cohorts were recruited through local blood donor registries; participants of the Utrecht (the Netherlands) and Florence (Italy) cohorts were recruited via breast cancer screening programs; the Oxford (United Kingdom) cohort included a large proportion of vegetarians. All participants signed an informed consent form and the study was approved by the ethical review committees of the International Agency for Research on Cancer (IARC) and EPIC centers.

For our study, we excluded participants with prevalent cancer at recruitment (n = 29,332), participants who were lost during follow-up (n = 124), participants for whom no dietary or lifestyle information was available (n = 6,259) and participants who were in the top or bottom 1% of the ratio of energy intake to estimated energy requirement (n = 9,573). After the exclusions, the final sample available for the analysis included 476,160 participants.

**Diet and lifestyle questionnaires**

Usual diet was assessed at recruitment using validated country-specific dietary questionnaires reflecting intake in the past 12 months. A separate questionnaire on lifestyle factors...
was used to collect information on smoking and alcohol consumption, education, occupation, reproductive history, family history and physical activity.

**Assessment of anthropometric and reproductive data**

Anthropometric measurements including height, weight, waist circumference (WC) and hip circumference (HC) were taken at recruitment by trained health professionals in most EPIC centers, except for most of the Oxford cohort, the Norwegian cohort and approximately two-thirds of the French cohort, in which height and weight were self-reported. BMI was computed as weight in kilograms divided by height in meters squared, waist-to-hip ratio (WHR) was computed as WC (cm) divided by HC (cm) and waist-to-height ratio (WHtR) was computed as WC (cm) divided by height (cm).

Information on reproductive history was collected at recruitment. The following reproductive characteristics were assessed: age at menarche, duration of menstrual cycle, ever been pregnant, age at first pregnancy, number of full-term pregnancies (parity), number of live-born children, breastfeeding, menopausal status, age at menopause, menopausal hormone use, oral contraceptive (OC) pill use and ovariectomy. More details on questionnaires can be found elsewhere.\(^{30,31}\)

**Follow-up and identification of cancer cases**

Participants were followed-up from study entry until cancer diagnosis, death or end of follow-up, which is currently up to 2015, whichever came first. Population-based cancer registries, as well as postal follow-up questionnaires, are used in most of the countries to identify incident cancer cases. In France, Germany, Greece and Naples (Italy) cancer cases are additionally identified through active follow-up. Data on mortality and movement of participants are obtained through periodic linkage to regional and national mortality registries. First primary incident esophageal and gastric cancers were coded according to the 10th revision of the International Classification of Diseases (ICD-10). Esophageal cancer included topography ICD-O codes C15.0–C15.9; EA was categorized as (ICD-O morphological codes: 8140, 8141, 8190–8231, 8260–8263, 8310, 8430, 8480–8490, 8560, 8570–8572) and ESCC was categorized as (ICD-O morphological codes: 8050–8076). Gastric adenocarcinomas included topography ICD-O codes: C16; GC was classified as ICD-O code C16.0 and GNC included C16.1–16.6.

**Statistical analysis**

Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between anthropometric and reproductive factors and risk of esophageal and gastric cancer by subtype and subsite, respectively. Age was used as the primary time metric, and entry time was defined as age at enrolment and exit time as age at diagnosis, death or end of follow-up, whichever occurred first. Models were stratified by age at recruitment and study center.

**Anthropometric variables.** To account for different body fat distributions of men and women, we used sex-specific tertiles for anthropometric variables (height, weight, WC, HC, WHR and WHtR). BMI was classified according to World Health Organization (WHO) categories: underweight (BMI < 18.5 kg/m\(^2\)), normal weight (18.5 ≤ BMI < 25 kg/m\(^2\)), overweight (25 ≤ BMI < 30 kg/m\(^2\)) and obese (≥30 kg/m\(^2\)). Mean and standard deviations or frequencies were calculated for baseline characteristics of study participants stratified by BMI categories. All models were adjusted for smoking status (never smoker; former smoker who stopped ≤10, 11–20 or 20+ years ago; current smoker of 1–15, 16–25 or 26+ cigarettes/day; current or occasional pipe/cigar; smoking unknown/missing), and education level (none, primary school, technical/professional, secondary school or university), while models for ESCC were additionally adjusted for alcohol intake (g/day). We also examined models in which BMI and WHR were mutually adjusted, to estimate whether abdominal obesity was associated with upper gastrointestinal cancers independently of the association with general obesity. In addition, separate models were used in which WC and HC were mutually adjusted for each other. Interactions between anthropometric variables with sex and smoking status were explored by including an interaction term along with the main effect term in the adjusted model. The likelihood ratio test was used to compare models with and without interaction terms.

**Reproductive variables.** Reproductive variables were classified into categories as follows: age at menarche (<12, 12–14, >14 years), duration of menstrual cycling (<30, 30–35, >35 years), ever been pregnant (yes/no), age at first pregnancy (<22, 22–26, >26 years), parity (0, 1–2, >2 pregnancies), number of live-born children (1, 2–3, >3), breastfeeding (yes/no), duration of breastfeeding (<4, 4–10, >10 months), menopausal status (pre/perimenopausal, postmenopausal), age at menopause (<48, 48–51, >51 years), menopausal hormone use (yes/no), duration of menopausal hormone use (<2, >2 years), OC pill use (yes/no), duration of OC pill use (<2, >2 years) and ovariectomy (no, unilateral, bilateral). We computed mean and standard deviations or frequencies for baseline characteristics in women stratified by OC and menopausal hormone use. Models for EA, GC and GNC were adjusted for smoking status, BMI and educational level, while models for ESCC were additionally adjusted for alcohol intake (g/day).

Tests for linear trend across categories of anthropometric and reproductive variables were performed by assigning the median value to each category as a continuous term in the Cox regression models.

To examine possible reverse causation, we performed sensitivity analyses by excluding esophageal and gastric cancer cases diagnosed in the first 2 years of follow up. Additional sensitivity analyses included restricting the analyses to participants in whom height and weight were measured rather than self-reported. To examine whether the excluded participants differed from those included, we compared the main baseline
characteristics in the included participants \((n = 476,160)\) to those participants with no dietary or lifestyle information \((n = 6,259)\).

All analyses were conducted using SAS 9.4 software (SAS Institute, Cary, NC) and \(p\) values <0.05 were considered statistically significant.

**Results**

During a mean follow-up of 14 years, 220 EA (171 men and 49 women), 195 ESCC (101 men and 94 women), 243 GC (163 men and 80 women) and 373 GNC (184 men and 189 women) cases were diagnosed among the 476,160 participants (142,241 men and 333,919 women).

**Anthropometric factors**

In the overall cohort, 1.1% of participants were underweight, 37.8% were normal weight, 30.9% were overweight and 12.4% were obese at baseline. Baseline characteristics by BMI categories are presented in Supporting Information Table S1. Obese men and women were slightly older, had a higher WC and HC, lower education level, less likely to be smokers, less physically active and had a higher prevalence of diabetes than normal weight subjects. In addition, obese men had a higher intake of fruits and vegetables.

Several anthropometric variables were positively associated with EA in both men and women (Tables 1 and 2), respectively, including BMI (obese vs. normal weight, men: HR 1.94, 95% CI: 1.25–3.03; women: HR 2.66, 95% CI: 1.15–6.19), WC (men: HR 2.39, 95% CI: 1.53–3.73 for >98 vs. <90 cm; women: HR 2.81, 95% CI: 1.13–6.96 for WC >84 vs. <74 cm), WHR (men: HR 2.91, 95% CI: 1.33–6.39 for >0.57 vs. <0.45), BMI and WHR were moderately correlated \((r = 0.43)\), as were WC and HC \((r = 0.67)\). Upon adjustment for WHR, BMI was no longer significantly associated with EA in men or women (HR 1.21, 95% CI: 0.75–1.97 and HR 1.93, 95% CI: 0.80–4.68 for obese vs. normal weight, respectively; Tables 3 and 4). Conversely, the positive association observed for WC and WHR in relation to EA remained significant in both men and women after adjustment for HC and BMI, respectively (Tables 3 and 4). Furthermore, the positive association observed between HC and EA in men was attenuated after adjustment for WC (Table 3). For ESCC, the inverse association observed with BMI and HC in men remained significant after adjustment for WHR and WC, respectively (Table 3). In contrast, a positive association was observed in men for ESCC with WC adjusted for HC (HR 2.14, 95% CI: 1.06–4.32 for WC >98 vs. <90 cm) and WHR adjusted for BMI (HR 2.24, 95% CI: 1.16–4.32 for WHR >0.96 vs. <0.91; Table 3). While in women, the inverse association observed for ESCC with WC and HC was no longer significant after mutual adjustment (Table 4).

After adjustment for BMI, WHR remained positively associated with GC in women (Table 4). A positive association was found between WC and GC in men after adjustment for HC (HR 1.99, 95% CI: 1.10–3.59 for >84 vs. <74 cm; Table 3). While the positive association observed for GC with WC in women was attenuated after adjustment for HC (HR 2.29, 95% CI: 0.92–5.72 for WC >84 vs. <74 cm; Table 4). For GNC, results did not change when we mutually adjusted for BMI and WHR or when WC and HC were mutually adjusted in either men or women (Tables 3 and 4).

No statistically significant interactions were observed between BMI or smoking status and any of the outcomes.

**Reproductive factors**

Baseline characteristics of women according to OC and menopausal hormonal use are presented in Supporting Information Table S2. Women who reported using OC pills were younger, had a slightly lower WC and HC, more educated, more likely to be smokers and more physically active, had a lower prevalence of diabetes compared to nonusers of OC. While women who reported using hormones for menopause were slightly older and less educated than nonusers.

We found no associations between reproductive factors and ESCC or GC (Table 5). However, an inverse association was observed between parity and EA (HR 0.38, 95% CI: 0.14–0.99 for >2 vs. 0 pregnancies). For GNC, compared to women who had their first pregnancy at an earlier age (<22 years), women who had their pregnancy at a later age (>26 years) had a lower risk of GNC (HR 0.54, 95% CI: 0.32–0.91). In addition, compared to women who had not undergone ovariectomy, women who had a bilateral ovariectomy had a higher risk of GNC (HR 1.87, 95% CI: 1.04–3.36), although there were only 13 cases in this group.
Table 1. Adjusted hazard ratios for esophageal and gastric cancer by subtype and subsite in men (n = 142,241) according to anthropometric factors in the EPIC study

|                | Esophageal cancer | Gastric cancer |     |     |     |     |
|----------------|-------------------|----------------|-----|-----|-----|-----|
|                | Adenocarcinoma    | Squamous cell carcinoma | Cardia | Noncardia | Cardia | Noncardia |
| Men^1          |                   |                 |     |     |     |     |
| Height (cm)    |                   |                 |     |     |     |     |
| <171           | 49 Reference      | 40 Reference    | 49 Reference | 87 Reference |     |     |
| 171–178        | 62 1.00 (0.68–1.47) | 32 0.64 (0.39–1.05) | 69 1.10 (0.75–1.63) | 74 1.03 (0.74–1.44) |     |     |
| >178           | 59 1.30 (0.87–1.96) | 29 0.74 (0.44–1.27) | 45 0.98 (0.63–1.53) | 22 0.49 (0.30–0.81) |     |     |
| Missing        | 1 – –             | – –             | – – | – – | – – | – – |
| \( \rho_{\text{trend}} \) | 0.30              | 0.21            | 0.81 | 0.008 |
| Weight (kg)    |                   |                 |     |     |     |     |
| <75            | 42 Reference      | 47 Reference    | 51 Reference | 64 Reference |     |     |
| 75–84          | 53 1.15 (0.76–1.73) | 26 0.49 (0.30–0.79) | 59 1.03 (0.70–1.51) | 64 0.91 (0.64–1.30) |     |     |
| >84            | 75 1.78 (1.21–2.63) | 28 0.51 (0.31–0.82) | 52 0.98 (0.65–1.45) | 53 0.84 (0.58–1.23) |     |     |
| Missing        | 1 – –             | – –             | 1 – | – – | – – | 3 – |
| \( \rho_{\text{trend}} \) | 0.006             | 0.003           | 0.96 | 0.68 |
| BMI (kg/m^2)   |                   |                 |     |     |     |     |
| Underweight^5  | – –               | 1 –             | 1 – | 1 – | 1 – | 1 – |
| Normal weight  | 50 Reference      | 53 Reference    | 51 Reference | 49 Reference |     |     |
| Overweight     | 83 0.91 (0.54–1.52) | 31 0.38 (0.24–0.61) | 90 1.22 (0.86–1.75) | 99 1.13 (0.79–1.62) |     |     |
| Obese          | 37 1.94 (1.25–3.03) | 16 0.52 (0.28–0.95) | 20 0.94 (0.55–1.61) | 32 1.03 (0.64–1.65) |     |     |
| Missing        | 1 – –             | 6 –             | 11 – | 3 – | 3 – | 3 – |
| \( \rho_{\text{trend}} \) | 0.02              | 0.0004          | 0.56 | 0.85 |
| Hip circumference (cm) |                   |                 |     |     |     |     |
| <98            | 35 Reference      | 48 Reference    | 54 Reference | 49 Reference |     |     |
| 98–103         | 67 1.75 (1.16–2.64) | 30 0.57 (0.36–0.91) | 53 0.90 (0.61–1.33) | 65 1.11 (0.76–1.62) |     |     |
| >103           | 52 1.59 (1.02–2.47) | 17 0.29 (0.16–0.54) | 45 0.90 (0.60–1.37) | 51 0.82 (0.54–1.26) |     |     |
| Missing        | 17 –              | 6 –             | 11 – | 3 – | 3 – | 3 – |
| \( \rho_{\text{trend}} \) | 0.03              | 0.0002          | 0.84 | 0.31 |
| Waist circumference (cm) |                   |                 |     |     |     |     |
| <90            | 30 Reference      | 29 Reference    | 32 Reference | 39 Reference |     |     |
| 90–98          | 50 1.46 (0.92–2.32) | 36 0.89 (0.54–1.47) | 66 1.54 (0.99–2.37) | 73 1.32 (0.88–1.97) |     |     |
| >98            | 75 2.39 (1.53–3.73) | 31 0.70 (0.41–1.21) | 55 1.41 (0.89–2.22) | 55 0.86 (0.55–1.34) |     |     |
| Missing        | 16 –              | 5 –             | 10 – | 17 – | 17 – | 17 – |
| \( \rho_{\text{trend}} \) | 0.0003             | 0.42            | 0.15 | 0.06 |
| Waist-to-hip ratio |                   |                 |     |     |     |     |
| ≤0.91          | 21 Reference      | 18 Reference    | 25 Reference | 32 Reference |     |     |
| 0.91–0.96      | 52 1.72 (1.02–2.90) | 36 1.17 (0.65–2.08) | 63 1.39 (0.87–2.22) | 81 1.42 (0.93–2.17) |     |     |
| ≥0.96          | 81 3.21 (1.93–5.34) | 41 1.26 (0.70–2.29) | 64 1.57 (0.97–2.53) | 52 0.90 (0.57–1.43) |     |     |
| Missing        | 17 –              | 6 –             | 11 – | 19 – | 19 – | 19 – |
| \( \rho_{\text{trend}} \) | <0.0001            | 0.74            | 0.19 | 0.03 |
| Waist-to-height ratio |                   |                 |     |     |     |     |
| ≤0.51          | 23 Reference      | 26 Reference    | 28 Reference | 26 Reference |     |     |
| 0.51–0.57      | 76 1.76 (1.09–2.86) | 43 0.80 (0.48–1.31) | 83 1.31 (0.84–2.03) | 82 1.29 (0.82–2.04) |     |     |
| ≥0.57          | 56 2.36 (1.40–3.97) | 27 0.69 (0.37–1.26) | 42 1.13 (0.68–1.88) | 59 1.02 (0.61–1.71) |     |     |
| Missing        | 16 –              | 5 –             | 10 – | 17 – | 17 – | 17 – |
| \( \rho_{\text{trend}} \) | 0.006              | 0.47            | 0.44 | 0.31 |

1Sex-specific tertiles were used in the analyses except for BMI.
2Stratified on age, center and adjusted for smoking and education level.
3Stratified on age, center and adjusted for smoking, education level and alcohol intake.
4Underweight (BMI <18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) and obese (BMI ≥30).
5We excluded underweight group from the analysis due to few number of cases.
Table 2. Adjusted hazard ratios for esophageal and gastric cancer by subtype and subsite in women ($n = 333,919$) according to anthropometric factors in the EPIC study

| Women* | Esophageal cancer |  | Squamous cell carcinoma |  | Gastric cancer |  | Noncardia |  |
|--------|-------------------|---|-------------------------|---|----------------|---|----------|---|
|        | Cases             | Adjusted HR* (95% CI) | Cases | Adjusted HR* (95% CI) | Cases | Adjusted HR* (95% CI) | Cases | Adjusted HR* (95% CI) |
| Height (cm) |  |  |  |  |  |  |  |  |
| <159   | 18                | Reference  | 20          | Reference  | 19          | Reference  | 74          | Reference  |
| 159–165| 13                | 0.58 (0.27–1.25) | 38          | 1.44 (0.82–2.55) | 29          | 1.26 (0.69–2.32) | 58          | 0.89 (0.61–1.28) |
| >165   | 16                | 1.01 (0.48–2.13) | 31          | 1.49 (0.80–2.76) | 23          | 1.29 (0.66–2.53) | 41          | 0.97 (0.63–1.51) |
| Missing| 2                 | –          | 5           | –          | 9           | –          | 16         | –          |
| $p_{\text{trend}}$ | 0.27       | 0.39       | 0.71       | 0.79 |
| Weight (kg) |  |  |  |  |  |  |  |  |
| <60    | 9                 | Reference  | 38          | Reference  | 12          | Reference  | 48          | Reference  |
| 60–69  | 15                | 1.29 (0.56–3.00) | 29          | 0.63 (0.38–1.03) | 22          | 1.63 (0.79–3.34) | 49          | 0.76 (0.51–1.14) |
| >69    | 23                | 1.88 (0.85–4.16) | 22          | 0.52 (0.30–0.90) | 37          | 2.77 (1.40–5.48) | 77          | 1.12 (0.77–1.64) |
| Missing| 2                 | –          | 5           | –          | 9           | –          | 15         | –          |
| $p_{\text{trend}}$ | 0.25       | 0.04       | 0.001      | 0.10 |
| BMI (kg/m$^2$)4 |  |  |  |  |  |  |  |  |
| Underweight5 | 1          | –          | 6           | –          | –           | –          | 2          | –          |
| Normal weight | 13         | Reference  | 45          | Reference  | 29          | Reference  | 68          | Reference  |
| Overweight | 22         | 2.15 (1.06–4.38) | 33          | 1.08 (0.68–1.72) | 30          | 1.44 (0.85–2.43) | 61          | 0.96 (0.67–1.38) |
| Obese    | 11                | 2.65 (1.15–6.19) | 5           | 0.50 (0.20–1.28) | 12          | 1.41 (0.70–2.83) | 42          | 1.31 (0.86–2.00) |
| Missing  | 2                 | –          | 5           | –          | 9           | –          | 16         | –          |
| $p_{\text{trend}}$ | 0.09       | 0.003      | 0.56       | 0.49 |
| Hip circumference (cm) |  |  |  |  |  |  |  |  |
| <96    | 14                | Reference  | 37          | Reference  | 13          | Reference  | 43          | Reference  |
| 96–104 | 14                | 0.78 (0.36–1.70) | 32          | 0.80 (0.49–1.31) | 29          | 1.83 (0.94–3.56) | 53          | 0.82 (0.54–1.24) |
| >104   | 18                | 1.11 (0.53–2.34) | 17          | 0.51 (0.28–0.95) | 26          | 1.97 (0.98–3.95) | 63          | 0.94 (0.62–1.44) |
| Missing| 3                 | –          | 8           | –          | 12          | –          | 30         | –          |
| $p_{\text{trend}}$ | 0.64       | 0.10       | 0.13       | 0.59 |
| Waist circumference (cm) |  |  |  |  |  |  |  |  |
| <74    | 7                 | Reference  | 29          | Reference  | 10          | Reference  | 35          | Reference  |
| 74–84  | 16                | 1.62 (0.65–4.08) | 35          | 0.71 (0.42–1.19) | 25          | 1.59 (0.75–3.36) | 50          | 0.79 (0.51–1.24) |
| >84    | 23                | 2.81 (1.13–6.96) | 22          | 0.55 (0.30–0.99) | 34          | 2.55 (1.22–5.33) | 74          | 0.97 (0.62–1.53) |
| Missing| 3                 | –          | 8           | –          | 11          | –          | 30         | –          |
| $p_{\text{trend}}$ | 0.06       | 0.13       | 0.03       | 0.47 |
| Waist-to-hip ratio |  |  |  |  |  |  |  |  |
| <0.76  | 4                 | Reference  | 23          | Reference  | 10          | Reference  | 23          | Reference  |
| 0.76–0.82 | 22          | 3.83 (1.28–11.44) | 37          | 0.90 (0.52–1.56) | 25          | 1.50 (0.71–3.17) | 69          | 1.54 (0.94–2.51) |
| >0.82  | 20                | 5.39 (1.74–16.72) | 26          | 0.73 (0.39–1.34) | 33          | 2.50 (1.19–5.25) | 67          | 1.49 (0.89–2.48) |
| Missing| 3                 | –          | 8           | –          | 12          | –          | 30         | –          |
| $p_{\text{trend}}$ | 0.01       | 0.57       | 0.03       | 0.21 |
| Waist-to-height ratio |  |  |  |  |  |  |  |  |
| <0.45  | 5                 | Reference  | 23          | Reference  | 9           | Reference  | 23          | Reference  |
| 0.45–0.52 | 18          | 1.87 (0.67–5.19) | 41          | 0.76 (0.44–1.31) | 31          | 1.53 (0.72–3.26) | 55          | 0.91 (0.54–1.52) |
| >0.52  | 23                | 3.50 (1.24–9.93) | 20          | 0.53 (0.27–1.03) | 29          | 2.05 (0.93–4.51) | 80          | 1.27 (0.75–2.16) |
| Missing| 3                 | –          | 10          | –          | 11          | –          | 31         | –          |
| $p_{\text{trend}}$ | 0.03       | 0.17       | 0.19       | 0.20 |

*Sex-specific tertiles were used in the analyses except for BMI.
1Stratified on age, center and adjusted for smoking, and education level.
2Stratified on age, center and adjusted for smoking, education level, and alcohol intake.
3Underweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) and obese (BMI ≥30).
4We excluded underweight group from the analysis due to few number of cases.

Sanikini et al.  
Int. J. Cancer: 00, 00–00 (2019) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
Exclusion of esophageal and gastric cancer cases diagnosed in the first 2 years of follow-up did not substantially change the associations observed for anthropometric or reproductive factors (data not shown). In addition, analyses restricted to measured anthropometric factors yielded similar results to those when participants with self-reported data were included (data not shown). Finally, comparing the baseline characteristics of included participants to those excluded from the analysis because they lacked dietary or lifestyle information, revealed no substantial differences between the two groups, except participants excluded were very slightly older than the included participants.

### Discussion

In this large prospective study, abdominal obesity was positively associated with EA and GC, while the findings for ESCC were less clear. No associations were observed for GNC either with general or abdominal obesity. With regards to reproductive factors in women, there were inverse associations between parity and EA and between age at first pregnancy and GNC; whereas a positive association was observed for bilateral ovariectomy and GNC.

A number of meta-analyses have shown that BMI was positively associated with EA and GC.\(^{11,12,32}\) Our study found a positive association between BMI and EA but these associations attenuated after adjustment for WHR, and no significant association was observed between BMI and GC independently of WHR. The NIH-AARP Diet and Health Study, a prospective cohort study of equivalent size to EPIC, showed a nonsignificant positive association between BMI and EA (HR 1.77, 95% CI: 0.90–3.49; for BMI \(\geq 35\) vs. 18.5 to <25) and a significant positive association between BMI and GC (HR 3.28, 95% CI: 1.76–6.11 for BMI \(\geq 35\) vs. 18.5 to <25) after adjustment for WHR.\(^{15}\) A nested case–control study also reported no

| Table 3. Adjusted hazard ratios for esophageal and gastric cancer by subtype and subsite in men (n = 142,241) according to anthropometric factors (mutually adjusted) in the EPIC study |
|---|---|---|---|---|---|---|---|---|
| | Esophageal cancer | Squamous cell carcinoma | Gastric cancer | Cardia | Noncardia |
| | | Adenocarcinoma | | | | | |
| Men* | | | | | | | |
| | Cases | Adjusted HR$^2$ (95% CI) | Cases | Adjusted HR$^2$ (95% CI) | Cases | Adjusted HR$^2$ (95% CI) | Cases | Adjusted HR$^2$ (95% CI) |
| **BMI (kg/m$^2$)**$^6$ adjusted for waist-to-hip ratio | | | | | | |
| Underweight$^5$ | – | – | 1 | – | 1 | – |
| Normal weight | 50 | Reference | 53 | Reference | 51 | Reference | 49 | Reference |
| Overweight | 83 | 0.88 (0.60–1.28) | 31 | 0.31 (0.19–0.50) | 90 | 1.06 (0.73–1.55) | 99 | 1.15 (0.79–1.67) |
| Obese | 37 | 1.21 (0.75–1.97) | 16 | 0.37 (0.19–0.71) | 20 | 0.75 (0.42–1.34) | 32 | 1.15 (0.69–1.92) |
| Missing | 1 | – | 1 | – | 3 | |
| $p_{\text{trend}}$ | 0.47 | <0.0001 | 0.51 | 0.83 |
| **Waist circumference (cm)** adjusted for hip circumference | | | | | |
| <90 | 30 | Reference | 29 | Reference | 32 | Reference | 39 | Reference |
| >90–98 | 50 | 1.41 (0.85–2.32) | 36 | 1.38 (0.80–2.36) | 66 | 1.87 (1.16–3.00) | 73 | 1.31 (0.84–2.05) |
| >98 | 75 | 2.67 (1.52–4.72) | 31 | 2.14 (1.06–4.32) | 55 | 1.99 (1.10–3.59) | 55 | 0.90 (0.51–1.59) |
| Missing | 16 | – | 5 | – | 10 | – | 17 | – |
| $p_{\text{trend}}$ | 0.001 | 0.11 | 0.03 | 0.14 |
| **Hip circumference (cm)** adjusted for waist circumference | | | | |
| <98 | 35 | Reference | 48 | Reference | 54 | Reference | 49 | Reference |
| >98–103 | 67 | 1.28 (0.80–2.04) | 30 | 0.42 (0.25–0.73) | 53 | 0.68 (0.44–1.05) | 65 | 1.06 (0.69–1.63) |
| >103 | 52 | 0.82 (0.47–1.45) | 17 | 0.17 (0.08–0.37) | 45 | 0.62 (0.36–1.06) | 51 | 0.92 (0.53–1.58) |
| Missing | 17 | – | 6 | – | 11 | – | 19 | – |
| $p_{\text{trend}}$ | 0.08 | <0.0001 | 0.15 | 0.79 |
| **Waist-to-hip ratio adjusted for BMI** | | | | |
| <0.91 | 21 | Reference | 18 | Reference | 25 | Reference | 32 | Reference |
| 0.91–0.96 | 52 | 1.82 (1.06–3.11) | 36 | 1.57 (0.87–2.84) | 63 | 1.37 (0.84–2.23) | 81 | 1.33 (0.86–2.06) |
| >0.96 | 81 | 3.47 (1.99–6.06) | 41 | 2.24 (1.16–4.32) | 64 | 1.60 (0.94–2.71) | 52 | 0.81 (0.49–1.35) |
| Missing | 17 | – | 6 | – | 11 | – | 19 | – |
| $p_{\text{trend}}$ | <0.0001 | 0.05 | 0.16 | 0.02 |

*Sex-specific tertiles were used in the analyses except for BMI.

Stratified on age, center and adjusted for smoking and education level.

Stratified on age, center and adjusted for smoking, education level and alcohol intake.

Underweight (BMI < 18.5), normal weight (18.5 \(\leq\) BMI < 25), overweight (25 \(\leq\) BMI < 30) and obese (BMI \(\geq\) 30).

We excluded underweight group from the analysis due to few number of cases.
association between BMI and EA after adjustment for abdominal diameter.33 In our study, WHR and WC were positively associated with EA independently of BMI and HC. WHR was also positively associated with GC in women only independently of BMI, and WC was positively associated between women and men after adjustment for HC. The NIH-AARP Diet and Health Study showed a positive association between WHR and EA (HR 1.17, 95% CI: 0.99–1.38; for Quartile 4 vs. Quartile 1), but no association between WHR and GC (HR 1.08, 95% CI: 0.71–1.57; for Quartile 4 vs. Quartile 1) when adjusted for BMI.15 This cohort study also showed a positive association between WC and risk of EA and GC, after adjustment for HC.15 In addition, two other cohort studies showed a positive association between WC and EA but these findings were not adjusted for HC.33,34 A recent meta-analysis of six prospective studies reported positive associations for GC with WC but not with WHR.35 Taken together, our findings show that WC and WHR rather than BMI appears to be more closely associated with EA and GC. These associations could potentially be explained by mechanical effects of obesity, especially abdominal obesity-promoting GERD, which is associated with an increased risk of EA and GC.16,33 In our study, the findings for ESCC were less clear; for example, in men, HC and BMI were inversely associated with ESCC, while WC and WHR were positively associated. A number of prospective cohort studies have reported an inverse association between BMI and ESCC.2,7,14 Few epidemiological studies have examined the association between abdominal obesity and ESCC and those that have reported no associations.33,34 The underlying mechanisms for the observed associations between adiposity and ESCC are not well-known and need to be further investigated but our study sheds further light on the contrasting observations for anthropometric measures and ESCC.
Table 5. Adjusted hazard ratios for esophageal and gastric cancer by subtype and subsite according to reproductive factors in women ($n = 333,919$) in the EPIC study

|                  | Esophageal cancer | Gastric cancer |          |
|------------------|-------------------|---------------|----------|
|                  | Adenocarcinoma    | Squamous cell carcinoma | Cardia | Noncardia |
| Cases            | Adjusted HR$^1$ (95% CI) | Adjusted HR$^2$ (95% CI) | Cases | Adjusted HR$^1$ (95% CI) | Cases | Adjusted HR$^1$ (95% CI) |
| Age at menarche, years |                  |                |          |          |          |          |
| <12              | 3                 | 0.38 (0.11–1.24) | 13      | 1.12 (0.60–2.07) | 8       | 0.77 (0.36–1.63) | 27       | 1.18 (0.77–1.83) |
| 12–14            | 38 Reference      | Reference      | 60      | Reference      | 52      | Reference      | 117      | Reference      |
| >14              | 6                 | 0.50 (0.21–1.21) | 17      | 0.83 (0.48–1.44) | 16      | 0.93 (0.53–1.64) | 33       | 0.91 (0.61–1.35) |
| Missing          | 2                 | –              | 4       | –              | 4       | –              | 12       | –              |
| $p_{\text{trend}}$ | 0.10              | 0.71           | 0.78    | 0.63           |          |          |          |          |
| Duration of menstrual cycle, years |                  |                |          |          |          |          |
| <30              | 5                 | Reference      | 14      | Reference      | 15      | Reference      | 36       | Reference      |
| 30–35            | 15                | 1.74 (0.57–5.35) | 29      | 1.02 (0.52–2.01) | 16      | 0.56 (0.26–1.22) | 63       | 1.23 (0.76–1.99) |
| >35              | 16                | 1.46 (0.48–4.48) | 34      | 1.14 (0.58–2.24) | 37      | 1.11 (0.57–2.18) | 63       | 1.04 (0.64–1.69) |
| Missing          | 13                | –              | 17      | –              | 12      | –              | 27       | –              |
| $p_{\text{trend}}$ | 0.62              | 0.90           | 0.01    | 0.56           |          |          |          |          |
| Ever been pregnant |                  |                |          |          |          |          |
| No               | 6                 | Reference      | 11      | Reference      | 5       | Reference      | 18       | Reference      |
| Yes              | 41                | 0.72 (0.30–1.72) | 80      | 0.99 (0.51–1.91) | 74      | 1.56 (0.63–3.89) | 158      | 0.95 (0.58–1.56) |
| Missing          | 2                 | –              | 3       | –              | 1       | –              | 13       | –              |
| $p_{\text{trend}}$ | 0.30              | 0.11           | 0.50    | 0.05           |          |          |          |          |
| Age at first pregnancy, years |                  |                |          |          |          |          |
| <22              | 6                 | Reference      | 22      | Reference      | 22      | Reference      | 38       | Reference      |
| 22–26            | 13                | 1.18 (0.43–3.23) | 25      | 0.54 (0.29–1.01) | 25      | 0.70 (0.38–1.27) | 55       | 0.65 (0.42–1.00) |
| >26              | 14                | 1.99 (0.70–5.59) | 15      | 0.53 (0.26–1.10) | 15      | 0.81 (0.40–1.64) | 31       | 0.54 (0.32–0.91) |
| Missing          | 16                | –              | 32      | –              | 18      | –              | 65       | –              |
| $p_{\text{trend}}$ | 0.12              | 0.13           | 0.64    | 0.98           |          |          |          |          |
| Parity (number of full-term pregnancies) |                  |                |          |          |          |          |
| 0                | 8                 | Reference      | 13      | Reference      | 7       | Reference      | 19       | Reference      |
| 1–2              | 27                | 0.69 (0.31–1.54) | 57      | 1.16 (0.62–2.18) | 47      | 1.34 (0.60–2.99) | 94       | 1.03 (0.62–1.70) |
| >2               | 10                | 0.38 (0.14–0.99) | 18      | 0.66 (0.32–1.38) | 23      | 1.10 (0.47–2.59) | 58       | 1.05 (0.62–1.80) |
| Missing          | 4                 | –              | 6       | –              | 3       | –              | 18       | –              |
| $p_{\text{trend}}$ | 0.18              | 0.40           | 0.54    | 0.91           |          |          |          |          |
| Number of live-born children |                  |                |          |          |          |          |
| 1                | 9                 | Reference      | 17      | Reference      | 10      | Reference      | 15       | Reference      |
| 2–3              | 23                | 0.54 (0.25–1.18) | 44      | 0.74 (0.41–1.35) | 38      | 0.79 (0.39–1.61) | 64       | 0.88 (0.50–1.57) |
| >3               | 4                 | 0.34 (0.09–1.31) | 6       | 0.52 (0.19–1.40) | 10      | 1.15 (0.46–2.88) | 16       | 0.91 (0.43–1.93) |
| Missing          | 13                | –              | 27      | –              | 22      | –              | 94       | –              |
| $p_{\text{trend}}$ | 0.18              | 0.40           | 0.54    | 0.91           |          |          |          |          |
| Ever breastfeed |                  |                |          |          |          |          |
| No               | 14                | Reference      | 20      | Reference      | 19      | Reference      | 43       | Reference      |
| Yes              | 29                | 0.63 (0.33–1.22) | 61      | 1.07 (0.64–1.81) | 54      | 0.86 (0.51–1.47) | 120      | 0.83 (0.58–1.19) |
| Missing          | 6                 | –              | 13      | –              | 7       | –              | 26       | –              |
| $p_{\text{trend}}$ | 0.77              | 0.77           | 0.90    | 0.67           |          |          |          |          |

(Continues)
Our study found no association for GNC with BMI, WC or WHR, which is in line with previous meta-analyses. However, we observed an inverse association between height and GNC in men only. Previous cohort studies that examined the association between height and GNC showed a nonsignificant inverse association. The observed association could potentially be explained by the positive association between GNC and _Helicobacter pylori_ infection, which may cause poor growth during childhood and has been associated with lower socioeconomic status, which is in turn related to poor nutrition and leads to shorter adult height.

With respect to reproductive factors, we found no associations between reproductive factors and ESCC or GC. However, an inverse association was observed between parity and EA. A meta-analysis by Wang _et al._ reported no association for EA with reproductive factors; however, this analysis did show an inverse association between breastfeeding and EA. A recent meta-analysis reported an inverse association between breastfeeding, parity and esophageal cancer.

Few epidemiological studies have studied the association between age at first pregnancy and upper gastrointestinal cancers. The Women’s Health Initiative Study reported no

---

Table 5. Adjusted hazard ratios for esophageal and gastric cancer by subtype and subsite according to reproductive factors in women (n = 333,919) in the EPIC study (Continued)

| Menopause status                  | Cases | Adjusted HR (95% CI) | Cases | Adjusted HR (95% CI) | Cases | Adjusted HR (95% CI) | Cases | Adjusted HR (95% CI) |
|----------------------------------|-------|----------------------|-------|----------------------|-------|----------------------|-------|----------------------|
| Pre/peri menopausal              | 9     | Reference            | 18    | Reference            | 23    | Reference            | 49    | Reference            |
| Post menopausal                  | 36    | 2.12 (0.76–5.89)     | 73    | 2.14 (0.95–4.79)     | 51    | 0.83 (0.39–1.76)     | 127   | 1.31 (0.72–2.38)     |
| Surgical menopause              | 4     | 3.66 (0.96–13.96)    | 3     | 1.45 (0.35–5.95)     | 6     | 1.70 (0.60–4.85)     | 13    | 2.26 (0.99–4.95)     |

| Age at menopause, years          |       |                      |       |                      |       |                      |       |                      |
|----------------------------------|-------|----------------------|-------|----------------------|-------|----------------------|-------|----------------------|
| <48                              | 10    | Reference            | 19    | Reference            | 13    | Reference            | 35    | Reference            |
| 48–51                            | 14    | 1.34 (0.58–3.13)     | 26    | 1.37 (0.74–2.55)     | 19    | 1.27 (0.62–2.60)     | 55    | 1.34 (0.87–2.07)     |
| >51                              | 4     | 0.51 (0.16–1.70)     | 18    | 1.20 (0.60–2.38)     | 15    | 1.34 (0.62–2.93)     | 34    | 0.98 (0.60–1.59)     |
| Missing                          | 21    | –                    | 31    | –                    | 33    | –                    | 65    | –                    |
| $p_{\text{trend}}$              |       | 0.24                 | 0.61  |                      | 0.73  |                      | 0.26  |                      |

| Ever use of hormones for menopause |       |                      |       |                      |       |                      |       |                      |
|-----------------------------------|-------|----------------------|-------|----------------------|-------|----------------------|-------|----------------------|
| No                                | 30    | Reference            | 58    | Reference            | 49    | Reference            | 119   | Reference            |
| Yes                               | 14    | 0.96 (0.49–1.89)     | 28    | 0.93 (0.57–1.53)     | 27    | 1.01 (0.61–1.67)     | 47    | 1.03 (0.71–1.50)     |
| Missing                           | 5     | –                    | 8     | –                    | 4     | –                    | 23    | –                    |

| Duration of hormone use for menopause (years) |       |                      |       |                      |       |                      |       |                      |
|-----------------------------------------------|-------|----------------------|-------|----------------------|-------|----------------------|-------|----------------------|
| <2                                           | 7     | Reference            | 12    | Reference            | 11    | Reference            | 15    | Reference            |
| ≥2                                           | 7     | 0.85 (0.28–2.62)     | 10    | 0.76 (0.30–1.94)     | 13    | 0.88 (0.37–2.06)     | 24    | 1.40 (0.69–2.84)     |
| Missing                                       | 35    | –                    | 72    | –                    | 56    | –                    | 150   | –                    |
| $p_{\text{trend}}$                          |       | 0.24                 | 0.61  |                      | 0.73  |                      | 0.26  |                      |

| Ever use of OC pill use                   |       |                      |       |                      |       |                      |       |                      |
|-------------------------------------------|-------|----------------------|-------|----------------------|-------|----------------------|-------|----------------------|
| No                                        | 25    | Reference            | 45    | Reference            | 36    | Reference            | 102   | Reference            |
| Yes                                       | 21    | 0.81 (0.41–1.58)     | 44    | 1.02 (0.61–1.69)     | 41    | 1.07 (0.64–1.78)     | 74    | 0.93 (0.66–1.33)     |
| Missing                                    | 3     | –                    | 5     | –                    | 3     | –                    | 13    | –                    |

| Duration of OC pill use (years)            |       |                      |       |                      |       |                      |       |                      |
|--------------------------------------------|-------|----------------------|-------|----------------------|-------|----------------------|-------|----------------------|
| <5                                         | 8     | Reference            | 16    | Reference            | 13    | Reference            | 28    | Reference            |
| ≥5                                         | 12    | 0.92 (0.37–2.32)     | 22    | 1.05 (0.52–2.11)     | 26    | 1.63 (0.81–3.30)     | 39    | 1.03 (0.61–1.73)     |
| Missing                                     | 29    | –                    | 56    | –                    | 41    | –                    | 122   | –                    |

| Ovarieectomy                                |       |                      |       |                      |       |                      |       |                      |
|---------------------------------------------|-------|----------------------|-------|----------------------|-------|----------------------|-------|----------------------|
| No                                          | 35    | Reference            | 66    | Reference            | 58    | Reference            | 119   | Reference            |
| Unilateral                                  | –     | –                    | 3     | 0.51 (0.13–2.11)     | 3     | 0.80 (0.25–2.55)     | 12    | 1.64 (0.88–3.06)     |
| Bilateral                                   | 4     | 1.94 (0.68–5.54)     | 3     | 0.73 (0.22–2.42)     | 6     | 1.98 (0.84–4.65)     | 13    | 1.87 (1.04–3.36)     |
| Missing                                     | 10    | –                    | 22    | –                    | 13    | –                    | 45    | –                    |

1Stratified on age, center and adjusted for smoking, BMI and education level.
2Stratified on age, center and adjusted for smoking, BMI, education level and alcohol intake.
association between age at first pregnancy and ESCC but this was restricted to postmenopausal women.\textsuperscript{26} Furthermore, a population-based case–control study showed no association between age at first pregnancy and distal gastric cancer (odds ratio: 0.83, 95% CI: 0.44–1.57, for ≥25 years vs. nulliparous).\textsuperscript{40} No other study has reported an inverse association between age at first pregnancy and GNC.

Our updated analysis with longer follow-up confirms the previously reported positive association between bilateral ovariectomy and GNC.\textsuperscript{28} While the NIH-AARP Diet and Health Study reported a nonsignificant increased risk for EA and GC combined ($n = 65$ cases) in women who had undergone ovariectomy,\textsuperscript{27} the Million Women’s Study Cohort reported no association with GC or GNC.\textsuperscript{25} As estrogen has been suggested as a protective factor for EA and gastric cancer,\textsuperscript{41,42} ovariectomy and consequentially decreased estrogen levels could explain the increased risk of GNC in these individuals. Interestingly, studies in animal models have shown that ovariectomized female mice had an increased risk of gastric cancer.\textsuperscript{41}

Our results suggest hormonal factors may play a role in the etiology of upper gastrointestinal cancers but the underlying biology is not defined. For gastric cancer, estrogens may protect against the development of this malignancy by acting on estrogen receptors (ER\textsubscript{α} and ER\textsubscript{β}), which have been identified in gastric cancer cells.\textsuperscript{43} Estrogen inhibits cell growth and increases apoptosis in gastric cancer cells\textsuperscript{44,45} and stimulates the expression of trefoil factor proteins, which play a role in mucosal protection and repair and their trefoil factor genes may act as tumor suppressors.\textsuperscript{41}

Estrogen regulates body adiposity and fat distribution through ER\textsubscript{s} in the brain, and by interacting with leptin pathways.\textsuperscript{46} Body fat distribution varies by sex as men tend to accrue more visceral fat, while women accrue more fat in the subcutaneous depot.\textsuperscript{47} Estrogen promotes the accumulation of subcutaneous fat\textsuperscript{48} and the decrease in estrogen levels in menopausal women is associated with an increase in visceral fat.\textsuperscript{49} The accumulation of visceral fat is associated with an increased risk of esophageal and gastric cancer.\textsuperscript{35} Hence, estrogen regulation of leptin levels in women may play a protective role directing accumulation of subcutaneous fat over visceral fat and consequently may explain the sex differences in the incidence of esophageal and gastric cancer.

However, any potential protective mechanisms associated with estrogen are in conflict with the fact that obesity, which has been linked with an increased risk of some upper gastrointestinal cancers, is associated with higher estrogen levels. Nevertheless, the associations observed in our study were site-specific, in that abdominal obesity was positively associated with EA and GC (and not GNC) and bilateral ovariectomy were only positively associated with GNC. Furthermore, in addition to the effect on sex hormones, there are other biological effects of obesity, including insulin resistance, where levels of insulin and bioavailability of IGF are increased, which promotes cell division and inhibits apoptosis.\textsuperscript{17} Obesity also increases concentrations of adipokines (e.g., leptin) and proinflammatory cytokines (e.g., tumor necrosis factor-α), which may contribute to cancer development.\textsuperscript{17,18}

Strengths of our study include its prospective study design, large sample size and availability of standardized information on reproductive factors, and potential confounders. In addition, anthropometric factors were mostly measured by trained professionals. Due to the prospective nature of the study, the likelihood of recall and selection bias is minimal. The large sample size allowed the analyses of esophageal and gastric cancer by subtype and subsite, and allowed analyses by gender; however, despite the size of the cohort and the long-term follow-up, the number of cases in some analyses was quite small. Our study has some limitations. We used a single assessment of anthropometric and reproductive factors collected at baseline as data during follow-up was not available; if anthropometric and reproductive factors changed during follow-up, this could lead to some misclassification and possibly bias the results toward null. Although we adjusted for several potential confounders, we lacked information on GERD and Helicobacter pylori infection, which have been associated with EA and GC, respectively; therefore, residual confounding cannot be excluded. We also lacked data on the reason for ovariectomy in the women who underwent this procedure. In addition, EPIC cohort participants are of European descent, which limits the generalizability of our findings to other ethnicities. Finally, as we analyzed anthropometric and reproductive factors in relation to both esophageal and gastric cancer by subtype and subsite, some of our associations may have arisen by chance as a result of multiple comparisons.

In conclusion, the results of our study suggest that abdominal obesity may influence risk for EA and GC. Furthermore, some reproductive factors in women may influence risk for EA and GNC, specifically. Together, these findings may support a role for hormonal pathways in upper gastrointestinal cancer development; however, in order to fully investigate these pathways, future studies should investigate endogenous hormone measurements in relation to these cancers. Considering these results, maintaining a healthy weight should be suggested as an evidence-based lifestyle recommendation for EA and GC prevention.

Acknowledgements

This research was funded by the Stand Up to Cancer campaign for Cancer Research UK. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM, France); German Cancer Aid, German Cancer Research Centre (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul
References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

2. World Cancer Research Fund and American Institute for Cancer Research. Diet, nutrition, physical activity and oesophageal cancer. Washington, DC: WCRF/AICR, 2016.

3. Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014;23:700–13.

4. Steffen A, Schulze MB, Pischon T, et al. Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2009;18:2079–89.

5. Steffen A, Huerta JM, Wijeratne E, et al. General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European prospective investigation into cancer and nutrition. Int J Cancer 2015;137:846–57.

6. Abnet CC, Freedman ND, Hollenbeck AR, et al. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer (Oxford, England: 1990) 2008;44:645–71.

7. Merry AH, Schouten LJ, Goldbohm RA, et al. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut 2007;56:1503–11.

8. Macinnes RJ, English DR, Hopper JL, et al. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int J Cancer 2006;118:2628–31.

9. Lindblad M, Rodrigue LA, Lagre J, Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 2005;16:285–94.

10. Ryan AM, Rowley SP, Fitzgerald AP, et al. Adenocarcinoma of the oesophagus and gastric cardia: male preponderance in association with obesity. Eur J Cancer (Oxford, England: 1990) 2006;42:1151–8.

11. Lauby-Secretan B, Scoccianti C, Loomis D, et al. World Health Organization International Agency for Research on Cancer Working Group. Smoke, tobacco use and related cancers: an overview of the evidence. Int J Cancer 2016;138:1–9.

12. Turati F, Tramacere I, La Vecchia C, et al. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol 2013;24:609–17.

13. World Cancer Research Fund and American Institute for Cancer Research. Diet, Nutrition, Physical activity and cancer: a Global Perspective. Washington, DC: WCRF/AICR, 2018.

14. Smith M, Zhou M, Whitlock G, et al. Esophageal cancer and body mass index: results from a prospective study of 220,000 men in China and a meta-analysis of published studies. Int J Cancer 2008;122:1604–10.

15. D’Oberghy MG, Freedman ND, Hollenbeck AR, et al. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP diet and health study. Gut 2012;61:1261–8.

16. Lagergren J. Influence of obesity on the risk of esophageal disorders. Nat Rev Gastroenterol Hepatol 2011;8:340–7.

17. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579–91.

18. Zheng J, Zhao M, Li J, et al. Obesity-associated digestive cancers: a review of mechanisms and interventions. Tumour Biol 2017;39:1010428317695020.

19. Xie SH, Lagergren J. The male predominance in esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2016;14:4338–47.

20. Sipponen P, Correa P. Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiological hypothesis. Gastric Cancer 2002;5:213–9.

21. Wang BI, Zhang B, Yan SS, et al. Hormonal and reproductive factors and risk of esophageal cancer in women: a meta-analysis. Dis Esophagus 2016;29:448–54.

22. Zha Y, Yue D, Yuan B, et al. Reproductive factors are associated with oesophageal cancer risk: results from a meta-analysis of observational studies. Eur J Cancer Prev 2017;26:1–9.

23. Camargo MC, Goto Y, Zabaleta J, et al. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21:20–38.

24. Wang Z, Butler LM, Wu AH, et al. Reproductive factors, hormone use and gastric cancer risk: the Singapore Chinese health study. Int J Cancer 2016;138:2837–45.

25. Green J, Roddam A, Pirie K, et al. Reproductive factors and risk of oesophageal and gastric cancer in the million women study cohort. Br J Cancer 2012;106:210–6.

26. Bodelon C, Anderson GL, Rossing MA, et al. Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. Cancer Prev Res (Phila) 2011;4:840–50.

27. Freedman ND, Lacey JV Jr, Hollenbeck AR, et al. The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP cohort. Cancer 2010;116:1572–81.

28. Duell EJ, Traversi N, Lujan-Barros L, et al. Menstrual and reproductive factors, exogenous hormone use, and gastric cancer risk in a cohort of women from the European prospective investigation into cancer and nutrition. Am J Epidemiol 2010;172:1384–93.

29. Rahmanaya S, Lambe M, Zenebehel K, et al. Parity and risk of stomach cancer by sub-site: a national Swedish study. Br J Cancer 2008/98: 1295–300.

30. Riboli E, Kaaks R. The EPIC project: rationale and study design. European prospective investigation into cancer and nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113–24.

31. Chen Y, Liu L, Wang X, et al. Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies. Cancer Epidemiol Biomarkers Prev 2013;22:1395–408.

32. Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cancer: a prospective study of 1010428317695020. Cancer Causes Control 2005;16:285–94.

33. Du X, Hidayat K, Shi BM. Abdominal obesity and gastroesophageal cancer risk: systematic review and meta-analysis of prospective studies. J Health Popul Nutr 2017;35:111–22.

34. Lin Y, Ness Jensen I, Hvbeam K, et al. Metabolic syndrome and esophageal and gastric cancer. Cancer Causes Control 2015;2015;26:1825–34.

35. Du X, Hidayat K, Shi BM. Abdominal obesity and gastroesophageal cancer risk: systematic review and meta-analysis of prospective studies. Proc Natl Acad Sci USA 2004;101:1463–8.

36. Goodman KJ, Correa P, Mera R, et al. Effect of Helicobacter pylori infection on growth velocity of school-age Andean children. Epidemiology 2011; 22:118–26.

37. Moayyedi P, Axon AT, Feltbower R, et al. Relation of adult lifestyle and socioeconomic factors to the prevalence of Helicobacter pylori infection. Int J Epidemiol 2002;31:624–31.
39. Dore MP, Pes GM, Sferlazzo G, et al. Role of Helicobacter pylori infection in body height of adult dyspeptic patients. *Helicobacter* 2016;21:575–80.

40. Frise S, Kreiger N, Gallinger S, et al. Menstrual and reproductive risk factors and risk for gastric adenocarcinoma in women: findings from the Canadian national enhanced cancer surveillance system. *Ann Epidemiol* 2006;16:908–16.

41. Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. *Eur J Cancer* 2008;44:2397–403.

42. Yang H, Sukacheva OA, Hussey DJ, et al. Estrogen, male dominance and esophageal adenocarcinoma: is there a link? *World J Gastroenterol* 2012;18:393–400.

43. Takano N, Iizuka N, Hazama S, et al. Expression of estrogen receptor-alpha and -beta mRNAs in human gastric cancer. *Cancer Lett* 2002;176:129–35.

44. Pricci M, Linsalata M, Russo F, et al. Effects of 17beta-estradiol administration on apoptosis and polyamine content in AGS cell line. *Anticancer Res* 2001;21:3215–20.

45. Zhou J, Teng R, Xu C, et al. Overexpression of ERalpha inhibits proliferation and invasion of MKN28 gastric cancer cells by suppressing beta-catenin. *Oncol Rep* 2013;30:1622–30.

46. Clegg DJ, Brown LM, Woods SC, et al. Gonadal hormones determine sensitivity to central leptin and insulin. *Diabetes* 2006;55:978–87.

47. Palmer BF, Clegg DJ. The sexual dimorphism of obesity. *Mol Cell Endocrinol* 2015;402:113–9.

48. Krotkiewski M, Bjorntorp P, Spostrom L, et al. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. *J Clin Invest* 1983;72:1150–62.

49. Toth MJ, Poehlman ET, Matthews DE, et al. Effects of estradiol and progesterone on body composition, protein synthesis, and lipoprotein lipase in rats. *Am J Physiol Endocrinol Metab* 2001;280:E496–501.
THE DIFFERENCE OF BREAKTHROUGH MOMENTS

WITH COMPLETE SOLUTIONS FOR GROUNDBREAKING DISCOVERIES FROM A TRUSTED PARTNER.

Your next breakthrough could be closer than you imagine, especially with the right resources to help you advance your research. At BD, we are dedicated to helping you get the data you need, when, where, and how you need it. Our integrated solutions in instrumentation, software and reagents are optimized to work together to bring you closer to your next breakthrough moment. And you can depend on us for world-class training, service and support to help you get the most from the results your research depends on. Discover a range of optimized solutions that open endless possibilities for your future research. Discover the new BD.

Learn how you can advance your research >